TY - JOUR
T1 - Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi
T2 - In silico, in vitro and in vivo activity studies
AU - Roldos, Virginia
AU - Nakayama, Hector
AU - Rolón, Miriam
AU - Montero-Torres, Alina
AU - Trucco, Fernando
AU - Torres, Susana
AU - Vega, Celeste
AU - Marrero-Ponce, Yovanni
AU - Heguaburu, Viviana
AU - Yaluff, Gloria
AU - Gómez-Barrio, Alicia
AU - Sanabria, Luis
AU - Ferreira, Maria Elena
AU - Rojas de Arias, Antonieta
AU - Pandolfi, Enrique
N1 - Funding Information:
This work was supported by grants from PDT (Project No. 29/194), PEDECIBA (Programa de Desarrollo de las Ciencias Básicas, URU/06/004). We wish to express our gratitude to Prof. Dr. Gustavo Seoane and Dr. Luis Rivas for helpful discussion and for critical review of the manuscript.
PY - 2008/9
Y1 - 2008/9
N2 - The synthesis and potent antiprotozoal activity of 14-hydroxylunularin, a natural hydroxybibenzyl bryophyte constituent is reported. 14-Hydroxylunularin was highly active in vitro assays against culture and intracellular forms of Leishmania spp. and Trypanosoma. cruzi, in absence of cytotoxicity against mammalian cells. Preliminary structure-activity relationship studies showed that the reported bioactivity depends on hybridization at the carbon-carbon bridge, position and number of free hydroxy group on the aromatic rings. The reported results were also in agreement with the in silico prediction using Non-Stochastic Quadratic Fingerprints-based algorithms. The same compound also showed antiprotozoal activity in Leishmania spp. infected mice by oral and subcutaneous administration routes, with an optimal treatment of a daily subcutaneous administration of 10 mg/kg of body weight for 15 days. This study suggested that 14-hydroxylunularin may be chosen as a new candidate in the development of leishmanicidal therapy.
AB - The synthesis and potent antiprotozoal activity of 14-hydroxylunularin, a natural hydroxybibenzyl bryophyte constituent is reported. 14-Hydroxylunularin was highly active in vitro assays against culture and intracellular forms of Leishmania spp. and Trypanosoma. cruzi, in absence of cytotoxicity against mammalian cells. Preliminary structure-activity relationship studies showed that the reported bioactivity depends on hybridization at the carbon-carbon bridge, position and number of free hydroxy group on the aromatic rings. The reported results were also in agreement with the in silico prediction using Non-Stochastic Quadratic Fingerprints-based algorithms. The same compound also showed antiprotozoal activity in Leishmania spp. infected mice by oral and subcutaneous administration routes, with an optimal treatment of a daily subcutaneous administration of 10 mg/kg of body weight for 15 days. This study suggested that 14-hydroxylunularin may be chosen as a new candidate in the development of leishmanicidal therapy.
KW - Bryophytes
KW - Hydroxybibenzyl constituents
KW - Leishmania
KW - TOMOCOMD software
KW - Trypanosoma cruzi
UR - http://www.scopus.com/inward/record.url?scp=51149091689&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2007.11.007
DO - 10.1016/j.ejmech.2007.11.007
M3 - Artículo
C2 - 18192088
AN - SCOPUS:51149091689
SN - 0223-5234
VL - 43
SP - 1797
EP - 1807
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
IS - 9
ER -